Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of PF-07220060 in Healthy Men
NCT06267963Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of atirmociclib in breast cancer, sponsored by Pfizer. Primary endpoints: Percentage of Total Radiocarbon (14C) Excreted in Urine at 14 days, Percentage of Total Radiocarbon (14C) Excreted in Feces at 14 days and 5 more. Started Jan 2024; status: completed.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06267963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267963.